Rare Intellectual Disabilities Clinical Trial
— MIDRIDOfficial title:
Multi-Omics and IPSCs to Improve the Diagnosis of Rare Intellectual Disabilities
| NCT number | NCT03635294 |
| Other study ID # | 49RC17_0224 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | January 9, 2019 |
| Est. completion date | March 2020 |
Background Genetic factors play a major role in intellectual disability (ID) but the
underlying cause is not determined in many cases.
This proposal is the continuation of the previous interregional project HUGODIMS, the aim of
which was to perform whole exome sequencing (WES) in 69 thoroughly selected simplex ID
parent-child trios. Thanks to HUGODIMS consortium, the underlying genetic cause of ID was
determined or highly suspected in 48 cases (69.5%) and 7 novel ID genes were identified.
Hypothesis Investigators hypothesize that an approach combining genomics, transcriptomics,
metabolomics and morphological analyses performed on induced pluripotent stem cell
(iPSC)-derived neural cells would improve diagnosis of ID. The current proposal is therefore
a proof-of concept project aiming at assessing the relevance and effectiveness of this
multi-omics approach.
Aims and Methods Ten individuals with ID recruited through HUGODIMS, in whom WES have failed
to identify pathogenic variants will be included.
The workflow is the following:
1. Whole genome sequencing (WGS) (Nantes) of these 10 negative trios.
2. Bio-informatics analyses
3. In 3 WGS negative cases, 3 positive controls bearing distinct mutations in CAMK2a (a
novel ID gene identified thanks to HUGODIMS), and 3 healthy negative controls:
1. Derivation of induced pluripotent stem cell (iPSC)-derived neural progenitors (iPSC
core facility at Nantes)
2. Targeted and non-targeted metabolomics analyses performed on iPSC-derived neuronal
cells (Angers)
3. RNA sequencing performed on the 9 cell lines (Rennes)
4. Morphological analyses of differentiated neuronal cell lines derived from 3
affected individuals and 3 positive controls bearing CMK2a mutations (Tours)
5. Integration and validation of data from multi-omics and morphological approaches
Expected results and impact Investigatrors expect that this approach combining multi-omics
and iPSC will help to improve diagnosis and understanding of genetic ID of unknown cause
| Status | Recruiting |
| Enrollment | 6 |
| Est. completion date | March 2020 |
| Est. primary completion date | March 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 2 Years to 25 Years |
| Eligibility |
Inclusion Criteria: - 3 Whole Genome Sequencing negative cases - 3 positive controls bearing distinct mutations in CAMK2a Exclusion Criteria: - no informed consent/refusal |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Angers | Angers | |
| France | HCL Lyon | Bron | |
| France | CHU de Bourgogne | Dijon | |
| France | CHU Nantes | Nantes | |
| France | CHU Poitiers | Poitiers | |
| France | CHU Rennes | Rennes |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Angers |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To evaluate the relevance and effectiveness of a multi-omics approach to the diagnosis of ID of unknown genetic origin. | Whole genome sequencing : de novo variants in non-coding regions of the genome, WGS will be performed using the HiSeq X Five System 5; Bionformatics analysis of WGS data; neuronal progenitors derived from iPSC | Day 1 | |
| Secondary | The assessment of metabolomics consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines | Coupled to high-resolution mass spectrometry ; Transcriptomics analyses: quality of the RNA will be evaluated with the Bioanalyzer (Agilent) on the basis of the RIN (RNA integrity number) as well as by taking into account the DV200, i.e. the percentage of RNA fragments with more than 200 nucleotides Non-targeted metabolomic analyses will be performed using a method based on ultra-high-performance liquid chromatography Flow injection analysis-tandem mass spectrometry for quantifying acylcarnitines, glycerophospholipids, sphingolipids and sugar, whereas liquid chromatography | Day 1 | |
| Secondary | The assessment of morphological consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines | immunocytochemistry and protein expression approaches using confocal microscopy and Western blotting with antibodies specific for proteins expressed in neurons (MAP2, Tubulin beta 3, PSD95, SNAP25), astrocytes (GFAP) or oligodendrocytes (Gal-C) | Day 1 |